Key points are not available for this paper at this time.
Atopic dermatitis represents a complex and multidimensional interaction that represents potential fields of preventive and therapeutic management. In addition to the treatment armamentarium available for atopic dermatitis, novel drugs targeting significant molecular pathways in atopic dermatitis biologics and small molecules are also being developed given the condition's complex pathophysiology. While most of the patients are expecting better efficacy and long-term control, the response to these drugs would still depend on numerous factors such as complex genotype, diverse environmental triggers and microbiome-derived signals, and, most importantly, dynamic immune responses. This review article highlights the challenges and the recently developed pharmacological agents in atopic dermatitis based on the molecular pathogenesis of this condition, creating a specific therapeutic approach toward a more personalized medicine.
Building similarity graph...
Analyzing shared references across papers
Loading...
Julius Garcia Gatmaitan
Ji Hyun Lee
International Journal of Molecular Sciences
Catholic University of Korea
Seoul St. Mary's Hospital
Lung Center of the Philippines
Building similarity graph...
Analyzing shared references across papers
Loading...
Gatmaitan et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69d7cdd011d83f35e5ae29c6 — DOI: https://doi.org/10.3390/ijms241411380